tirzepatide vs semaglutide vs. semaglutide: Study compares cost and health outcomes in obesity Tirzepatide vs semaglutide for weight

The FDA sent this letter shortly before the agencys April 30 proposal to exclude three weight loss drugs, including tirzepatide, from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. ProRx and, reportedly, BPI Labs ceased producing these drugs in April, while Medisource stopped in March after its parent company, Hims, decided to cease sales of compounded semaglutide

Yay, Im in favor of that

These labs inform dosing decisions and identify contraindications before the first prescription

doi: 10.1167/iovs.65.8.16 343 TangY.LiT.LiJ.YangJ.LiuH.ZhangX